...
ABUSSMALL

Arbutus Biopharma Corporation

HealthcareBiotechnology
$4.66
$0.00(-0.85%)
52W$2.71
$5.10
FinancialsValuationvs ALNY
Updated Mar 2, 12:00 AM
RSI65
RS Rating68/99
Beta0.94
Volatility47%
F-Score3/9
Mkt Cap$895M
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Arbutus Biopharma Corporation is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 68), indicating performance broadly in line with the market. Earnings growth of 60% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
68
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.94
vs S&P 500
MARKET
52W Position
82%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$4.38
50 SMA > 100 SMA$4.42
100 SMA > 150 SMA$4.25
150 SMA > 200 SMA$4.01

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$4.19+11.20%ABOVE
50 SMA$4.38+6.45%ABOVE
100 SMA$4.42+5.34%ABOVE
150 SMA$4.25+9.61%ABOVE
200 SMA$4.01+16.15%ABOVE

Price Performance

1D-0.9%
1W+6.2%
1M+12.6%
3M+5.7%
6M+27.0%
YTD-2.3%
1Y+35.1%
3Y+18.8%
52-Week Trading Range82% from low
$4.66
52W Low$2.71
52W High$5.10

Technical Indicators

RSI (14)BULLISH
65.2
305070
VCP ScoreWARM
7/10
Base depth: 33.7%

Risk Profile

Beta
0.94
52W Vol
47%
ATR
$0.23
Max DD (1Y)
-26%

Volume Analysis

Today
4
50D Avg
1.40M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24+39%
$-0.07
Q1'25-30%
$-0.13
Q2'25+112%
$0.01
Q3'25+60%
$-0.04
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:-8.50%
5 Years:+0.53%
3 Years:-17.50%
TTM:+116.64%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+46.57%

Stock Price CAGR

10 Years:+3.96%
5 Years:+3.95%
3 Years:+18.79%
1 Year:+35.07%

Return on Equity

10Y Avg:-61.1%
5Y Avg:-60.7%
3Y Avg:-58.0%
Last Year:-54.6%

Key Metrics

Market Cap$895M
Gross Margin1.0%
Net Margin-11.3%
Piotroski F-Score3/9

More ABUS Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

ABUS vs ALNYALNYIONSARWRCRSP

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 68 meansABUS outperformed 68% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.94 means 6% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 3/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 7/10 with WARM status.

Frequently Asked Questions

Is ABUS in an uptrend right now?

ABUS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is ABUS overbought or oversold?

ABUS's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.

Is ABUS outperforming the market?

ABUS has a Relative Strength (RS) Rating of 68 out of 99. ABUS is performing about average compared to the market.

Where is ABUS in its 52-week range?

ABUS is trading at $4.66, which is 91% of its 52-week high ($5.10) and 82% above its 52-week low ($2.71).

How volatile is ABUS?

ABUS has a Beta of 0.94 and 52-week volatility of 47%. It's less volatile than the S&P 500 - generally more stable.